Evidence map›Paper›PMID 40722341›Full record

ArticleBrain sciences2025

Subtyping Early Parkinson's Disease by Mapping Cognitive Profiles to Brain Atrophy with Visual MRI Ratings.

Tania Álvarez-Avellón, Carmen Solares, Juan Álvarez-Carriles, Manuel Menéndez-González

Abstract read
In one paragraph

Article in Brain sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Cognitive profiles at presentation and subsequent cognitive decline and quality of life in Parkinson's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tania Álvarez-AvellónDepartamento de Psicología, Universidad de Oviedo, 33009 Oviedo, Spain.
Carmen SolaresInstituto de Investigación Sanitaria del Principado de Asturias, 33011 Oviedo, Spain.ORCID 0000-0001-6656-8836
Juan Álvarez-CarrilesDepartamento de Psicología, Universidad de Oviedo, 33009 Oviedo, Spain.
Manuel Menéndez-GonzálezInstituto de Investigación Sanitaria del Principado de Asturias, 33011 Oviedo, Spain.ORCID 0000-0002-5218-0774

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCognitive heterogeneity in Parkinson's disease (PD) remains a diagnostic and prognostic challenge, particularly in early stages. In this cross-sectional study, we aimed to identify clinically relevant cognitive subtypes in early PD by integrating neuropsychological profiles with regional brain atrophy assessed via visual MRI scales.

methodsEighty-one de novo PD patients (≤36 months from diagnosis) and twenty healthy controls underwent 3T MRI with visual atrophy ratings and completed an extensive neuropsychological battery.

resultsUsing a mixed a priori-a posteriori approach, we defined eight anatomocognitive subtypes reflecting distinct patterns of regional vulnerability: frontosubcortical, posterior cortical, left/right hippocampal, global, and preserved cognition. Specific MRI markers correlated with cognitive deficits in executive, visuospatial, memory, and language domains. Cluster analyses supported subtype validity (AUC range: 0.68-0.95).

conclusionsThese results support a practical classification model linking cognitive performance to brain structural changes in early PD. This scalable approach may improve early patient stratification and guide personalized management strategies. Longitudinal studies are needed to assess progression patterns and therapeutic implications.

Indexed as

cognitive declineneuroanatomyParkinson’s diseasestructural MRIvisual atrophy scales

Identifiers

PMID40722341
PMCPMC12294059

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.